Table 3.
Cross tabulation of study results.
| Compartment | Areas investigated for DE | Index tests | TP (%) | FP (%) | TN (%) | FN (%) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | LR+ (95% CI) | LR− (95% CI) | Accuracy (95% CI) | p-value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anterior compartment | Bladder | TVS | 8 (16.3%) | 0 (0.0%) | 40 (81.6%) | 1 (2%) | 0.89 (0.52–1.00) | 1.00 (0.91–1.00) | 1.00 (1.00–1.00) | 0.98 (0.86–1.00) | Infinity | 0.11 (0.02–0.71) | 0.98 (0.89–1.00) | 0.25 |
| MRI | 9 (18.3%) | 2 (4.1%) | 38 (77.6%) | 0 (0.0%) | 1.00 (0.66–1.00) | 0.95 (0.83–0.99) | 0.82 (0.54–0.95) | 1.00 (1.00–1.00) | 20 (5.1–77.2) | 0.00 | 0.96 (0.86–0.99) | |||
| Ureteric obstruction by DE | TVS/TAS | 5 (10.2%) | 0 (0.0%) | 44 (89.8%) | 0 (0.0%) | 1.00 (0.48–1.0) | 1.00 (0.92–1.00) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | Infinity | 0.00 | 1.00 (0.93–1.00) | 1.000 | |
| MRI | 5 (10.2%) | 0 (0.0%) | 44 (89.8%) | 0 (0.0%) | 1.00 (0.48–1.0) | 1.00 (0.92–1.0) | 1.00 (1.00–1.00) | 100 (1.00–1.00) | Infinity | 0.00 | 1.00 (0.93–1.00) | |||
|
| ||||||||||||||
| Posterior compartment | USL§ | TVS | 25 (51%) | 5 (10.2%) | 10 (20.4%) | 9 (18.3%) | 0.74 (0.56–0.87) | 0.67 (0.38–0.88) | 0.83 (0.70–0.91) | 0.53 (0.36–0.68) | 2.21 (1.05–4.64) | 0.40 (0.20–0.77) | 0.71 (0.57–0.83) | 0.039 |
| MRI | 32 (65.3%) | 6 (12.2%) | 9 (18.3%) | 2 (4.1%) | 0.94 (0.80–0.99) | 0.60 (0.32–0.84) | 0.84 (0.74–0.91) | 0.82 (0.52–0.95) | 2.35 (1.26–4.40) | 0.10 (0.02–0.40) | 0.84 (0.70–0.93) | |||
| Right USL | TVS | 10 (20.4%) | 5 (10.2%) | 26 (53%) | 8 (16.3%) | 0.56 (0.31–0.78) | 0.84 (0.66–0.95) | 0.67 (0.45–0.83) | 0.76 (0.65–0.85) | 3.44 (1.40–8.50) | 0.53 (0.31–0.91) | 0.73 (0.59–0.85) | 0.001 | |
| MRI | 17 (34.7%) | 11 (22.4%) | 20 (40.8%) | 1 (2%) | 0.94 (0.73–1.00) | 0.65 (0.45–0.81) | 0.61 (0.49–0.72) | 0.95 (0.75–0.99) | 2.66 (1.63–4.33) | 0.09 (0.01–0.59) | 0.76 (0.61–0.87) | |||
| Left USL | TVS | 21 (42.9%) | 0 (0.0%) | 23 (46.9%) | 5 (10.2%) | 0.81 (0.61–0.93) | 1.00 (0.85–1.00) | 1.00 (1.00–1.00) | 0.82 (0.68–0.91) | 0.00 | 0.19 (0.09–0.42) | 0.90 (0.78–0.97) | 0.220 | |
| MRI | 23 (46.9%) | 2 (4.1%) | 21 (42.9%) | 3 (6.1%) | 0.88 (0.70–0.98) | 0.91 (0.72–0.99) | 0.92 (0.75–0.98) | 0.88 (0.71–0.95) | 10.17 (2.69–38.52) | 0.13 (0.04–0.37) | 0.90 (0.78–0.97) | |||
| Upper rectum | TVS | 10 (20.4%) | 0 (0.0%) | 39 (79.6%) | 0 (0.0%) | 1.00 (0.69–1.00) | 1.00 (0.91–1.00) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | Infinity | 0.00 | 1.00 (0.93–1.00) | 1.000 | |
| MRI | 10 (20.4%) | 0 (0.0%) | 39 (79.6%) | 0 (0.0%) | 1.00 (0.66–0.89) | 1.00 (0.91–1.00) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | Infinity | 0.00 | 1.00 (0.93–1.00) | |||
| Rectosigmoid | TVS | 16 (32.7%) | 5 (10.2%) | 27 (55.1%) | 1 (2%) | 0.94 (0.71–1.00) | 0.84 (0.67–0.95) | 0.76 (0.59–0.88) | 0.96 (0.80–0.99) | 6.20 (2.67–13.59) | 0.07 (0.01–0.47) | 0.88 (0.75–0.95) | 1.000 | |
| MRI | 16 (32.7%) | 5 (10.2%) | 27 (55.1%) | 1 (2%) | 0.94 (0.71–1.00) | 0.84 (0.67–0.95) | 0.76 (0.59–0.88) | 0.96 (0.80–0.99) | 6.20 (2.67–13.59) | 0.07 (0.01–0.47) | 0.88 (0.75–0.95) | |||
| RVS | TVS | 4 (8.2%) | 0 (0.0%) | 43 (87.8%) | 2 (4.1%) | 0.67 (0.22–0.96) | 1.00 (0.92–1.00) | 1.00 (1.00–1.00) | 0.96 (0.87–0.98) | Infinity | 0.33 (0.11–1.03) | 0.96 (0.86–1.00) | 0.125 | |
| MRI | 5 (10.2%) | 3 (6.1%) | 40 (81.6%) | 1 (2%) | 0.83 (0.36–1.00) | 0.93 (0.81–0.99) | 0.63 (0.35–0.84) | 0.98 (0.87–1.00) | 11.9 (3.79–37.67) | 0.18 (0.03–1.07) | 0.92 (0.80–0.98) | |||
| Vagina | TVS | 6 (12.2%) | 0 (0.0%) | 38 (77.6%) | 5 (10.2%) | 0.55 (0.23–0.83) | 1.00 (0.91–1.00) | 1.00 (1.00–1.00) | 0.88 (0.80 –0.94) | Infinity | 0.45 (0.24–0.87) | 0.90 (0.78–0.97) | 0.688 | |
| MRI | 8 (16.3%) | 2 (4.1%) | 36 (73.5%) | 3 (6.1%) | 0.73 (0.39–0.94) | 0.95 (0.82–0.99) | 0.80 (0.50–0.94) | 92.31 (0.82–0.97) | 13.82 (3.42–55.9) | 0.29 (0.11–0.76) | 0.90 (0.78–0.97) | |||
| POD obliteration | TVS | 35 (71.5%) | 1 (2%) | 8 (16.3%) | 5 (10.2%) | 0.88 (0.73–0.96) | 0.89 (0.52–1.00) | 0.97 (0.85–1.00) | 0.62 (0.41–0.79) | 7.87 (1.24–50.16) | 0.14 (0.06–0.33) | 0.88 (0.75–0.95) | 0.040 | |
| MRI | 23 (46.9%) | 5 (10.2%) | 4 (8.2%) | 17 (34.7%) | 0.58 (0.41–0.73) | 0.44 (0.14–0.79) | 0.82 (0.71–0.90) | 0.19 (0.09–0.35) | 1.03 (0.54–1.97) | 0.96 (0.42–2.16) | 0.55 (0.40–0.69) | |||
|
| ||||||||||||||
| Pelvis | Overall pelvic DE∗∗ | TVS | 80 (20.4%) | 10 (2.5%) | 280 (71.4%) | 22 (5.6%) | 0.78 (0.69–0.86) | 0.97 (0.94–0.98) | 0.89 (0.81–0.94) | 0.93 (0.90–0.95) | 22.8 (12.30–42.20) | 0.22 (0.15–0.32) | 0.92 (0.89–0.94) | |
| MRI | 93 (23.7%) | 25 (6.4%) | 265 (67.6%) | 9 (2.3%) | 0.91 (0.84–0.96) | 0.91 (0.88–0.94) | 0.79 (0.72–0.84) | 0.97 (0.94–0.98) | 10.58 (7.24–15.46) | 0.10 (0.05–0.18) | 0.91 (0.88–0.94) | |||
§At least one affected side correctly identified. ∗∗Total DE lesions are the sum of all individual sites affected in all participants. CI, confidence intervals; DE, deep endometriosis; FN, false negative; FP, False positive; LR+, positive likelihood ratio; LR−, negative likelihood ratio; MRI, magnetic resonance imaging; NPV, negative predictive value; p-value, probability value of ultrasound vs. MRI performance (<0.05 considered significant); POD, pouch of Douglas; PPV, positive predictive value; RVS, rectovaginal septum; USL, uterosacral ligament; TAS, transabdominal ultrasound scan; TN, true negative TP, true positive; TVS, transvaginal ultrasound scan.